A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

Clinical trial NCT05475925 · RECRUITING

Trial details

NCT number: NCT05475925
Sponsor: Dren Bio
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

LGLL - Large Granular Lymphocytic Leukemia Primary Cutaneous Gamma-Delta T-Cell Lymphoma Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma Hepatosplenic T-cell Lymphoma Subcutaneous Panniculitis-Like T-Cell Lymphoma Aggressive NK Cell Leukemia Systemic EBV1 T-cell Lymphoma, if CD8 Positive Hydroa Vacciniforme-Like Lymphoproliferative Disorder Extranodal NK/T Cell Lymphoma, Nasal Type Enteropathy-Associated T-Cell Lymphoma Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma Cytotoxic PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)

Start date: 2022-07-13
Primary completion: 2026-12-01
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.